Protocol Ledger

NCT07299019 · Phase III · RECRUITING

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Interventional Phase III clinical trial protocol NCT07299019 sponsored by Zenas BioPharma (USA) in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-23 Enrollment: 990 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07299019
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)990 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07299019
Protocol FieldVerified Registry Value
NCT IdentifierNCT07299019
Consolidated Lead SponsorZenas BioPharma (USA)
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment990 participants (ESTIMATED)
Registered Start Date2026-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07299019
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI